Staff Scientist

Selected Publications:

Research Interests:
Dhivya’s research interests are cellular signaling and identification of novel molecular targets. She is working on obtaining the mechanistic insights into tyrosine kinases, and nuclear hormone receptors such as androgen receptor (AR) in immune regulation and cancer development. The study aims to identify and assess AR-kinase signaling mediated epigenetic regulation and molecular alterations in prostate cancer. Novel small molecule inhibitors developed to target ACK1 and WEE1 kinases are also assessed for their therapeutic potential as novel drugs for cancer treatment. In addition, ACK1/TNK2 Knock-out mice model is used to assess the functional significance of ACK1 as an immune modulator.

1. Sridaran D, Chouhan S, Mahajan K, Weimholt C, Bhagwat S, Reimers M, Pachynski RK, Seeliger M, Miller TW, Feng FY, Mahajan NP*. Inhibiting ACK1-mediated phosphorylation of C-terminal Src kinase counteracts prostate cancer immune checkpoint blockade resistance. Nature Communications, 2022.

2.  Nguyen T, Sridaran D, Chouhan S, Weimholt C, Wilson A, Luo J, Li T, Koomen J, Fang B, Putluri N, Sreekumar A, Feng FY, Mahajan K, and Mahajan NP*. Epigenetic Control of Androgen Production by Histone H2A K130 acetylation. Nature Communications, 2023. 

3. Sawant M, Wilson A, Sridaran D, Mahajan K, O’Conor C, Hagemann I, Luo J, Weimholt C, Li T, Roa JC, Wu X, Pandey A, Mahajan NP*. Epigenetic Reprogramming of Cell Cycle Genes by ACK1 Promotes Breast Cancer Resistance to CDK4/6 Inhibitor. Oncogene, 42, pages 2263–2277, 2023.

4. Sridaran D, Bradshaw E, Deselm C, Pachynski R, Mahajan K, Mahajan NP*. Prostate cancer immunotherapy: Improving clinical outcomes with a multi-pronged approach. Cell Reports Medicine, 2023.

5. Chouhan S, Sridaran D, Weimholt C, Luo J, Li T, Hodgson MC, Santos LN, Sommer SL, Fang B, Koomen JM, Qu C-K, Yart A, Kontaridis MI, Mahajan NP*. SHP2 as a Primordial Epigenetic Enzyme Expunges Histone H3 pTyr-54 to Amend Androgen Receptor Homeostasis. Nature Communications, 2024.

6. Sridaran D, and Mahajan NP*. Tracking ACK1/TNK2 kinase: Signaling, Diseases and Therapeutic Implications. 2024.

Dhivya Sridaran

MSc, VIT University

PhD, Bharathidasan University

Contact:

Email: dhivyasridaran@wustl.edu

Phone: 314 273-7759